Drug Patents owned by Viiv Hlthcare
1. List of Apretude drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(3 years from now) | |
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11224597 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR ingredient
NCE-1 date: 2025-01-21
Market Authorisation Date: 20 December, 2021
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
APRETUDE family patents
32
United States
13
Japan
12
European Union
9
Spain
7
Hungary
7
Slovenia
7
Denmark
6
Portugal
6
Korea, Republic of
6
Poland
5
Norway
5
Lithuania
4
Mexico
4
Hong Kong
4
Cyprus
4
Israel
3
Brazil
3
China
3
Taiwan, Province of China
3
EA
3
South Africa
3
Canada
3
Australia
2
Morocco
2
Luxembourg
2
Ukraine
2
Netherlands
1
Croatia
1
San Marino
1
New Zealand
1
Philippines
1
Austria
1
ME
1
Viet Nam
1
Chile
1
RS
2. List of Cabenuva Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8080551 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(21 days from now) | |
| US7125879 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(2 years from now) | |
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(3 years from now) | |
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11389447 | VIIV HLTHCARE | Aqueous suspensions of TMC278 |
Jun, 2027
(4 years from now) | |
| US11224597 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 21, 2026 |
| New Patient Population (NPP) | Mar 29, 2025 |
| New Dosing Schedule (D) | Jan 31, 2025 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 2025-01-21
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy; Treatment of hiv infection in adults; Treatment of hiv-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
CABENUVA KIT family patents
67
United States
35
European Union
23
Japan
21
Norway
21
Hungary
16
Spain
14
Korea, Republic of
13
Slovenia
13
Denmark
12
Lithuania
12
Australia
11
Portugal
11
China
11
Poland
10
Brazil
9
Mexico
9
Hong Kong
9
Israel
8
Croatia
8
Taiwan, Province of China
8
EA
8
Canada
8
Cyprus
7
Luxembourg
6
New Zealand
6
South Africa
6
Ukraine
5
AP
4
Austria
4
Argentina
3
Belgium
3
RS
3
Netherlands
2
Singapore
2
Malaysia
2
Jordan
2
Costa Rica
2
Morocco
2
Nicaragua
2
ME
2
Chile
1
Germany
1
Uruguay
1
Panama
1
San Marino
1
Egypt
1
Philippines
1
Peru
1
Viet Nam
1
OA
3. List of Dovato drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(4 years from now) | |
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11234985 | VIIV HLTHCARE | Antiviral therapy |
Jan, 2031
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Aug 6, 2023 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 08 April, 2019
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
DOVATO family patents
48
United States
22
Japan
18
European Union
12
Spain
11
Korea, Republic of
10
Hungary
10
Australia
9
Mexico
9
Slovenia
9
Denmark
8
Portugal
8
Hong Kong
8
Canada
8
Israel
8
Poland
7
Norway
7
Lithuania
6
EA
6
Cyprus
5
New Zealand
5
China
4
Singapore
4
Brazil
3
Croatia
3
Philippines
3
Morocco
3
Taiwan, Province of China
3
South Africa
3
Luxembourg
3
RS
2
Russia
2
Dominican Republic
2
Peru
2
ME
2
Ukraine
2
Netherlands
1
Turkey
1
Malaysia
1
Costa Rica
1
San Marino
1
Colombia
1
AP
1
Austria
1
Tunisia
1
Viet Nam
1
Chile
1
Ecuador
4. List of Juluca drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8080551 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(21 days from now) | |
| US7125879 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(2 years from now) | |
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(4 years from now) | |
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(6 years from now) | |
| US10426780 | VIIV HLTHCARE | Antiviral therapy |
Jan, 2031
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101629 | VIIV HLTHCARE | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug, 2022
(7 months ago) | |
Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 November, 2017
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
JULUCA family patents
78
United States
37
European Union
31
Japan
23
Norway
23
Hungary
18
Spain
18
Korea, Republic of
18
Australia
14
Slovenia
14
Denmark
13
Mexico
13
Hong Kong
13
Lithuania
12
Portugal
12
China
12
Canada
12
Israel
12
Poland
10
Brazil
10
EA
9
Croatia
9
New Zealand
9
Cyprus
8
Luxembourg
7
Taiwan, Province of China
6
South Africa
5
Singapore
5
AP
5
Ukraine
4
Austria
4
RS
3
Malaysia
3
Costa Rica
3
Philippines
3
Argentina
3
Morocco
3
Belgium
3
ME
3
Netherlands
2
Russia
2
Dominican Republic
2
Peru
2
Nicaragua
1
Turkey
1
Germany
1
Panama
1
Jordan
1
San Marino
1
Colombia
1
Egypt
1
Tunisia
1
Viet Nam
1
OA
1
Chile
1
Ecuador
5. List of Rukobia drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8461333 | VIIV HLTHCARE | Salts of prodrugs of piperazine and substituted piperidine antiviral agents |
Feb, 2025
(1 year, 11 months from now) | |
| US7745625 | VIIV HLTHCARE | Prodrugs of piperazine and substituted piperidine antiviral agents |
Nov, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168615 | VIIV HLTHCARE | Prodrugs of piperazine and substituted piperidine antiviral agents |
Feb, 2025
(1 year, 11 months from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 2, 2025 |
Drugs and Companies using FOSTEMSAVIR TROMETHAMINE ingredient
NCE-1 date: 2024-07-02
Market Authorisation Date: 02 July, 2020
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
RUKOBIA family patents
16
United States
2
New Zealand
2
China
2
Hong Kong
2
Israel
1
Portugal
1
Germany
1
Malaysia
1
Russia
1
Spain
1
Brazil
1
Croatia
1
Norway
1
Austria
1
Argentina
1
Peru
1
Taiwan, Province of China
1
Korea, Republic of
1
South Africa
1
Japan
1
Canada
1
Cyprus
1
Slovenia
1
Ukraine
1
Georgia
1
Poland
1
Australia
1
RS
1
Denmark
1
European Union
6. List of Selzentry drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6667314
(Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Feb, 2022
(1 year, 1 month ago) | |
| US7368460 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Nov, 2022
(3 months ago) | |
|
US7368460
(Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
May, 2023
(2 months from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Oct 30, 2023 |
| Pediatric Exclusivity (PED) | Apr 30, 2024 |
Drugs and Companies using MARAVIROC ingredient
Market Authorisation Date: 04 November, 2016
Treatment: Method of treating patients infected with ccr5-tropic hiv-1
Dosage: SOLUTION;ORAL
SELZENTRY family patents
5
United States
3
Germany
3
Malaysia
3
Spain
3
Norway
3
China
3
Hong Kong
3
European Union
2
Portugal
2
United Kingdom
2
Austria
2
Argentina
2
Korea, Republic of
2
EA
2
Japan
2
Slovenia
2
Australia
2
Denmark
1
Turkey
1
Uruguay
1
Panama
1
Guatemala
1
Brazil
1
Croatia
1
Costa Rica
1
IB
1
New Zealand
1
AP
1
Egypt
1
Estonia
1
Mexico
1
Morocco
1
Peru
1
Taiwan, Province of China
1
Tunisia
1
South Africa
1
Slovakia
1
Lithuania
1
Canada
1
Cyprus
1
ME
1
Luxembourg
1
Czech Republic
1
Iceland
1
Israel
1
Ukraine
1
OA
1
Bulgaria
1
Georgia
1
Poland
1
Yugoslavia
1
RS
1
Algeria
1
Ecuador
1
Cuba
1
Netherlands
1
Hungary
7. List of Tivicay drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(4 years from now) | |
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(6 years from now) | |
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
Market Authorisation Date: 12 August, 2013
Treatment: NA
Dosage: TABLET;ORAL
TIVICAY family patents
33
United States
15
Japan
13
European Union
9
Spain
7
Korea, Republic of
6
Hungary
6
Slovenia
6
Denmark
5
Portugal
5
Norway
5
Mexico
5
Hong Kong
5
Poland
4
Lithuania
4
Canada
4
Australia
3
Brazil
3
China
3
Taiwan, Province of China
3
Cyprus
3
Israel
2
Russia
2
Morocco
2
EA
2
South Africa
2
Luxembourg
2
Netherlands
1
Singapore
1
New Zealand
1
Philippines
1
Austria
1
Ukraine
1
Viet Nam
8. List of Tivicay Pd drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(4 years from now) | |
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(6 years from now) | |
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
Market Authorisation Date: 12 June, 2020
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
TIVICAY PD family patents
33
United States
15
Japan
13
European Union
9
Spain
7
Korea, Republic of
6
Hungary
6
Slovenia
6
Denmark
5
Portugal
5
Norway
5
Mexico
5
Hong Kong
5
Poland
4
Lithuania
4
Canada
4
Australia
3
Brazil
3
China
3
Taiwan, Province of China
3
Cyprus
3
Israel
2
Russia
2
Morocco
2
EA
2
South Africa
2
Luxembourg
2
Netherlands
1
Singapore
1
New Zealand
1
Philippines
1
Austria
1
Ukraine
1
Viet Nam
9. List of Triumeq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(4 years from now) | |
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(6 years from now) | |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 22 August, 2014
Treatment: NA
Dosage: TABLET;ORAL
TRIUMEQ family patents
33
United States
15
Japan
13
European Union
9
Spain
7
Korea, Republic of
6
Hungary
6
Slovenia
6
Denmark
5
Portugal
5
Norway
5
Mexico
5
Hong Kong
5
Poland
4
Lithuania
4
Canada
4
Australia
3
Brazil
3
China
3
Taiwan, Province of China
3
Cyprus
3
Israel
2
Russia
2
Morocco
2
EA
2
South Africa
2
Luxembourg
2
Netherlands
1
Singapore
1
New Zealand
1
Philippines
1
Austria
1
Ukraine
1
Viet Nam
10. List of Triumeq Pd drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(4 years from now) | |
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(6 years from now) | |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 30 March, 2022
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
TRIUMEQ PD family patents
33
United States
15
Japan
13
European Union
9
Spain
7
Korea, Republic of
6
Hungary
6
Slovenia
6
Denmark
5
Portugal
5
Norway
5
Mexico
5
Hong Kong
5
Poland
4
Lithuania
4
Canada
4
Australia
3
Brazil
3
China
3
Taiwan, Province of China
3
Cyprus
3
Israel
2
Russia
2
Morocco
2
EA
2
South Africa
2
Luxembourg
2
Netherlands
1
Singapore
1
New Zealand
1
Philippines
1
Austria
1
Ukraine
1
Viet Nam
11. List of Vocabria drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(3 years from now) | |
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 21, 2026 |
| New Patient Population (NPP) | Mar 29, 2025 |
| M (M) | Jan 31, 2025 |
Drugs and Companies using CABOTEGRAVIR SODIUM ingredient
NCE-1 date: 2025-01-21
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 in an adult in combination with rilpivirine
Dosage: TABLET;ORAL
VOCABRIA family patents
26
United States
12
Japan
11
European Union
8
Spain
6
Hungary
6
Slovenia
6
Denmark
5
Portugal
5
Norway
5
Korea, Republic of
5
Poland
4
Hong Kong
4
Lithuania
3
Mexico
3
Cyprus
3
Israel
2
Brazil
2
Morocco
2
China
2
Taiwan, Province of China
2
EA
2
South Africa
2
Canada
2
Luxembourg
2
Australia
2
Netherlands
1
New Zealand
1
Philippines
1
Austria
1
Ukraine
1
Viet Nam
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic